Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Iparomlimab
Mucosal Melanoma
Fudan UniversityP2CCC (53)
Irinotecan
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Ivocizumab
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP2CCC (53)
Ivocizumab
Neuroendocrine Carcinoma
Fudan UniversityP2CCC (53)
Ivocizumab
Renal Cell Carcinoma
Fudan UniversityP2CCC (53)
Ivocizumab
Extramammary Paget Disease
Fudan UniversityP2CCC (53)
Ivocizumab
Penile Cancer
Fudan UniversityP2CCC (53)
Ivocizumab
Pheochromocytoma/Paraganglioma
Fudan UniversityP2CCC (53)
Ivocizumab
Prostate Cancer
Fudan UniversityP2CCC (53)
Ivocizumab
Kidney Angiomyolipoma
Fudan UniversityP2CCC (53)
Ivocizumab
Lung Sarcomatoid Carcinoma
Fudan UniversityP2CCC (53)
Ivocizumab
Urachus Cancer
Fudan UniversityP2CCC (53)
Ivonescimab
Metastatic Malignant Neoplasm In The Brain
Fudan UniversityP2CCC (53)
Ivonescimab
Breast Neoplasm
Fudan UniversityP2CCC (53)
Ivonescimab
Breast Tumors
Fudan UniversityP2CCC (53)
Ivonescimab
ctDNA
Fudan UniversityP2CCC (53)
Ivonescimab
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Ivonescimab
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Ivonescimab
Metastatic Breast Cancer ( HER2 Negative)
Fudan UniversityP2CCC (53)
js207
Breast Neoplasm
Fudan UniversityP2CCC (53)
js207
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
js207
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Jskn003
Breast Neoplasm
Fudan UniversityP2CCC (53)
Jskn003
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Jskn003
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Showing 301 to 325 of 615 assets
PreviousPage 13 of 25Next